Immuno-oncology has spent 15 years releasing the brakes.

TATUM Bioscience is developing 

multi-pathway immune engagers that reprogram tumors from within to generate systemic and durable antitumor immunity. By combining multiple clinically validated immune pathways in a single agent, our technology is built to activate, expand and sustain the immune response where checkpoint inhibitors fail.